- Home
- OI vs ABCL Comparison
OI vs ABCL Comparison
Compare OI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | ABCL |
|---|---|---|
| Founded | 1903 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OI | ABCL |
|---|---|---|
| Price | $7.55 | $5.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $15.29 | $8.40 |
| AVG Volume (30 Days) | 3.1M | ★ 5.4M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,426,000,000.00 | $75,128,000.00 |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $1.88 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $7.75 | $2.75 |
| 52 Week High | $16.91 | $8.44 |
Technical Indicators
Market Signals| Indicator | OI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 39.61 |
| Support Level | N/A | $5.17 |
| Resistance Level | $9.75 | $5.63 |
| Average True Range (ATR) | 0.53 | 0.44 |
| MACD | -0.14 | -0.21 |
| Stochastic Oscillator | 8.88 | 17.10 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.